Market Cap | 293.31M | P/E | - | EPS this Y | -4.20% | Ern Qtrly Grth | - |
Income | -54.81M | Forward P/E | -7.39 | EPS next Y | 58.10% | 50D Avg Chg | -16.00% |
Sales | 13.59M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 3.87 | EPS next 5Y | - | 52W High Chg | -36.00% |
Recommedations | 1.70 | Quick Ratio | 6.20 | Shares Outstanding | 36.05M | 52W Low Chg | 123.00% |
Insider Own | 6.59% | ROA | -31.67% | Shares Float | 18.32M | Beta | 0.05 |
Inst Own | 76.47% | ROE | -99.97% | Shares Shorted/Prior | 4.78M/4.65M | Price | 8.20 |
Gross Margin | 71.96% | Profit Margin | - | Avg. Volume | 451,262 | Target Price | 19.50 |
Oper. Margin | -250.28% | Earnings Date | May 8 | Volume | 295,161 | Change | -1.32% |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
HC Wainwright & Co. | Buy | Mar 14, 24 |
Craig-Hallum | Buy | Sep 7, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
HC Wainwright & Co. | Buy | Aug 2, 23 |
HC Wainwright & Co. | Buy | Jul 19, 23 |
HC Wainwright & Co. | Buy | Jun 8, 23 |
Maxim Group | Buy | May 11, 23 |
HC Wainwright & Co. | Buy | May 11, 23 |
HC Wainwright & Co. | Buy | Mar 23, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Nov 25 | Buy | 5.25 | 762,380 | 4,002,495 | 5,328,328 | 11/29/22 |
5AM Partners IV, LLC | 10% Owner 10% Owner | Sep 06 | Sell | 5.14 | 226,622 | 1,164,837 | 503,112 | 09/08/22 |
5AM Partners IV, LLC | 10% Owner 10% Owner | Apr 11 | Sell | 5 | 270,000 | 1,350,000 | 537,301 | 04/13/22 |